Background. Virus-like particles (VLPs) of Ebola virus (EBOV) and Marburg virus (MARV) produced in human 293T embryonic kidney cells have been shown to be effective vaccines against filoviral infection. In this study, we explored alternative strategies for production of filovirus-like particle-based vaccines, to accelerate the development process. The goal of this work was to increase the yield of VLPs, while retaining their immunogenic properties.
Enveloped virus-like particles (VLPs) of Ebola virus (EBOV) and Marburg virus (MARV) can be generated easily in a mammalian expression system by introduction of the appropriate gene encoding EBOV or MARV VP40 matrix protein [1] [2] [3] [4] . Coexpression of other proteins, including glycoprotein (GP), matrix proteins (VP24 and VP40), and nucleoprotein (NP), alone or in combination will result in the generation of filoviruslike particles containing these viral antigens [5] [6] [7] [8] [9] [10] . These Ebola VLPs (eVLPs) and Marburg VLPs (mVLPs) retain a morphology that is remarkably similar to that of authentic virions [1] [2] [3] [4] . VLPs potently stimulate functional maturation and activation of dendritic cells (DCs) in vitro, which likely is responsible or absence of adjuvant, mice are protected in a dose-dependent manner from a range of challenge doses (∼10-1000 pfu or ∼300-30,000 LD 50 ) [11, 15] . Guinea pigs vaccinated with eVLPs or mVLPs develop high levels of virus-specific and -neutralizing antibodies in serum [5, 6, 13] . The addition of adjuvant, such as saponin-derived QS-21 or RIBI, to filovirus-like particlebased vaccines should allow dose sparing and should shorten vaccination times while still maintaining complete protection against challenge [5, 6, 11, 13, 15] .
Baculovirus-derived subunit vaccines are currently being tested for a multitude of viruses [16] [17] [18] [19] . The advantage of using a baculovirus expression system is that it should facilitate the scaleup to large-batch manufacturing for clinical grade vaccines. In a recent study, Ye et al. [20] reported the production of eVLPs by use of a recombinant baculovirus expression system. In addition, Hevey et al. [21] and Mellquist-Riemenschneider et al. [22] demonstrated the immunogenicity of baculovirus-derived recombinant MARV and EBOV GP, respectively, with complete protection observed in MARV-infected but not EBOV-infected guinea pigs. In this study, we cloned EBOV and MARV GP, NP, and VP40 genes into separate baculovirus constructs. The recombinant baculoviruses then were simultaneously used to coinfect insect cells, to generate VLPs that incorporated VP40, NP, and GP. These VLPs then were characterized by biochemical, microscopic, immunological, and animal efficacy studies.
MATERIALS AND METHODS
Generation of eVLPs and mVLPs. Mammalian 293T cellderived eVLPs and mVLPs were prepared essentially as described elsewhere [8, 11, 13, 23] . In brief, human embryonic 293T kidney cells were cotransfected with GP, NP, and VP40 genes from Zaire EBOV (ZEBOV) and MARV (Musoke strain), cloned in pWRG vectors, by use of Lipofectamine 2000 (Invitrogen). After 48-72 h, cell supernatants were collected, cleared of cellular debris by low-speed centrifugation, and then pelleted at 9500 g for 4 h. The crude VLP preparations were separated on a 20%-60% continuous sucrose gradient, concentrated by a second centrifugation, and resuspended in endotoxin-free PBS.
For expression in an insect cell system, the same genes as mentioned above were cloned by use of Gateway recombinational cloning into pDest-8 (Invitrogen), a baculovirus expression vector containing the polyhedrin late promoter. Bacmid DNA was generated by in vivo transposition in Escherichia coli, and DNA was transfected into Sf9 insect cells. Recombinant baculovirus containing the filoviral proteins of interest were recovered from supernatants and amplified with another passage through Sf9 cells. The final viruses were introduced into High Five (Hi5) insect cells, the VLPs were recovered from the culture supernatants by high-speed centrifugation and purification on sucrose gradients, as briefly described above and as reported elsewhere [8, 11, 13, 23] .
Expression analysis. Western blot analysis of the VLP preparations was performed, after separation on 4%-12% Tris-glycine gels (Invitrogen), by use of monoclonal antibodies recognizing ZEBOV or MARV GP, VP40, and NP, followed by detection with a goat antimouse horseradish peroxide-conjugated antibody and enhanced chemiluminescence [6, 8, 21, [23] [24] [25] . VLPs were processed and imaged by electron microscopy, as described elsewhere [8, 11, 13, 23] . In brief, the particles were applied to formvar-and carbon-precoated grids, treated with 1% glutaraldehyde, rinsed in distilled water, negatively stained with uranyl acetate, and examined on a JEOL EX transmission electron microscope at 80 kV.
Filoviruses. ZEBOV, mouse-adapted EBOV, and MARV (Musoke strain) were propagated and counted by a standard plaque assay on Vero or Vero E6 cells [26] . Filovirus-infected cells and animals were handled by qualified personnel under maximum containment in a biosafety level 4 laboratory at the US Army Medical Research Institute of Infectious Diseases (Fort Detrick, MD).
Culture and stimulation of primary human DCs. DCs were cultured from peripheral blood, as described elsewhere [12, 27, 28] . In short, primary adherent human monocytes were isolated after enrichment of peripheral blood mononuclear cells (PBMCs), by centrifugation over ficoll-hypaque, and then were selected by plastic adherence and cultured in complete RPMI 1640 supplemented with 100 ng/mL recombinant human granulocyte-macrophage colony-stimulating factor and 20 ng/mL recombinant human interleukin (IL)-4 (PeproTech). One-third of the medium and 100% of each cytokine were replaced every other day. The resulting differentiated DCs were 197% CD1a positive and !1% CD14 negative. DCs were incubated in medium alone or with mammalian 293T cell-or insect cell-derived eVLPs or mVLPs (50 mg per cells) or polyinosinic- 6 1 ϫ 10 polycytidylic acid double-stranded RNA (25 mg/mL). After 48 h, the stimulated cells were washed in cold PBS and 10% fetal bovine serum (FBS), and cell-surface staining was done by use of the following antibodies: fluorescein isothiocyanate (FITC)-conjugated anti-CD80; phycoerythrin (PE)-conjugated anti-CD86; FITC-conjugated anti-HLA-DR; PE-conjugated anti-HLA-A, -B, and -C; PE-conjugated anti-CD11c; PE-conjugated anti-CD1a; FITC-conjugated anti-mouse IgG1; and PE-conjugated anti-mouse IgG2b (PharMingen). After incubation with antibodies, cells were washed and fixed with 10% buffered formalin. The cells were analyzed with a FACSCalibur flow cytometer (Becton Dickinson). A minimum of 10,000 events were collected and analyzed for each sample.
Vaccinations. Female C57BL/6 mice, 6-8 weeks old (National Cancer Institute, Frederick Cancer Research and Development Center), were vaccinated intramuscularly on days 0 and 21 with 10 mg of mammalian 293T cell-derived or baculovirus-derived eVLPs containing GP, NP, and VP40 mixed with 10 mg of QS-21 adjuvant (kindly provided by Antigenics) and diluted in endotoxin-free PBS. Control mice were vaccinated on the same schedule with 10 mg of QS-21 adjuvant in PBS. Serum samples were obtained from each mouse on days 0 and 49 after vaccination. Mice were challenged ∼4 weeks after the second vaccination, by intraperitoneal injection with 1000 pfu (∼30,000 LD 50 ) of mouse-adapted EBOV diluted in PBS [29] . After challenge, mice were observed at least twice daily for illness. Throughout the experiment, mice were housed in microisolator cages and provided with autoclaved water and chow ad libitum.
Research was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adhered to principles stated in the Guide for the Care and Use of Laboratory Animals [30] . The facility where this research was conducted Figure 3 . Stability of insect cell-derived virus-like particles (VLPs). Ebola VLPs were stored in PBS at 4؇C or in PBS and 15% glycerol at Ϫ80؇C for the indicated number of days and were subjected to Western blot analysis with anti-glycoprotein (GP) and anti-VP40 antibodies (A). VLPs stored at 4؇C (B) or Ϫ80؇C (C) for 45 days were analyzed by electron microscopy (magnification, ϫ12,000).
is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (Rockville, MD).
Immune responses after vaccination. Levels of EBOV-specific antibodies were determined by ELISA, as described elsewhere [6, 13] . In brief, the wells were coated with sucrosepurified and g-irradiated/inactivated ZEBOV. End-point titers were established as the inverse of the last dilution in which the optical density of the sample was у0.2 higher than that in the corresponding control wells (irrelevant heterologous antigen).
T cell responses in VLP-vaccinated mice were determined by use of a peptide restimulation assay and were assessed by interferon (IFN)-g production, as described elsewhere [15, 31] . Splenocytes were isolated and cultured at 37ЊC for 5 h in the presence of 1-5 mg of peptide(s) or phorbol 12-myristate 13-acetate (PMA at 25 ng/mL) and ionomycin (1.25 mg/mL). Cells were blocked with a monoclonal antibody against the FcRIII/ II receptor and stained with anti-CD44 FITC and anti-CD8 or anti-CD4 Cy-Chrome (Pharmingen) with brefeldin A. After fixation in 1% formaldehyde and permeabilization in 0.5% saponin, the cells were stained with anti-IFN-g-PE and analyzed by use of flow cytometry. Samples with an increase in the frequency of IFN-g-positive cells of 12-fold above background, as assessed by responses to an irrelevant peptide (Lassa virus N: (RPLSAGVYMGNLSSQ) or no peptide stimulation, were considered to be positive.
RESULTS
Generation of baculovirus-derived VLPs. mVLPs containing GP, NP, and VP40 based on the Musoke strain of Lake Victoria marburgvirus were generated by coinfection of insect cells with recombinant baculoviruses containing the individual genes. Using electron microscopy ( figure 1A and 1B) and Western blotting techniques ( figure 1C) , we determined that the baculovirus-derived mVLPs had properties similar to those we had observed previously for mVLPs from mammalian cells [6, 8, 13] .
We then biochemically and immunogenically characterized eVLPs generated in insect cells. First, using only the 2 filovirus proteins required for efficient VLP budding, VP40 and GP, we examined the protein expression from the recombinant baculovirus-infected Sf9 and Hi5 cells. After expression of both constructs separately and together, VP40 and GP was detected in insect cell detergent-soluble and -insoluble fractions and cell supernatants, by PAGE and Coomassie staining (figure 2). In the insect cell detergent-soluble and -insoluble fractions, a large amount of VP40 was located in the soluble fraction (∼60%), whereas mostly GP was found in the insoluble fraction (170%). When expressed alone, VP40 was readily detectable in culture supernatant, by Coomassie staining, whereas the expression of GP in supernatant was less pronounced (figure 2). In contrast to that in the mammalian system [10, 23] , coinfection with GP did not appear to improve secreted VP40 levels, although there was a modest decrease in intracellular VP40 levels. Intracellular levels of GP also were lower during coinfection (figure 2).
Long-term stability of baculovirus-derived VLPs. To determine the long-term stability of the baculovirus-derived eVLPs, a single batch of eVLPs was stored in aliquots in PBS at 4ЊC or in PBS and 15% glycerol at Ϫ80ЊC. At various time points after the eVLPs were made, individual aliquots were analyzed for protein and particle content by Western blot or electron microscopy (figure 3). eVLPs were fairly stable under both conditions for at least 45 days, although the eVLPs stored at Ϫ80ЊC appeared to be slightly more preserved (figure 3). Furthermore, eVLPs stored for 16 months are equally as efficacious in mice as are freshly prepared eVLPs (authors' unpublished data).
Generation of insect cell-derived eVLPs containing GP, NP, and VP40. We also generated eVLPs containing GP, NP, and VP40. The addition of NP did not appear to alter the efficiency of eVLP production in the insect cells, unlike that found with mammalian cells [9, 10] . Although electron microscopy ( figure  4A-4C ) of the baculovirus-derived eVLPs indicated that they were indistinguishable from mammalian 293T cell-derived eVLPs, Western blot analysis showed differences in the migration of the GP molecule in the insect cell-derived VLPs, compared with that in mammalian 293T cell-derived VLPs ( figure  4D ). GP from the baculovirus-derived VLPs had a slightly smaller molecular weight than did the GP from the mammalian 293T cell-derived VLPs; this difference is likely due to differences in the ability of the insect cells to glycosylate proteins [32, 33] . High-magnification images of the baculovirus-derived eVLPs revealed the characteristic 90-100-nm diameter and apparent nucleocapsid structures inside the particles (figure 4B), as would be expected for filovirus particles [34] . Induction of maturation and activation of human DCs by baculovirus-derived VLPs. Optimal stimulation of the immune response against a pathogen requires both phenotypic and functional maturation of DCs. Phenotypic maturation of DCs was assessed by an increase in the expression of specific cell-surface markers, including those required for antigen presentation (major histocompatibility complex [MHC] I and MHC II) and costimulatory activity (CD80 and CD86). We previously demonstrated that mammalian 293T cell-derived VLPs induce maturation and activation of mouse and human myeloid DCs [11, 12] . Both baculovirus-and mammalian 293T cell-derived eVLPs containing GP and VP40 caused increased surface expression of CD80, CD86, MHC I, MHC II, and CD83 ( figure 5 ). In addition, exposure to the baculovirus-or mammalian 293T cell-derived eVLPs induced secretion of proinflammatory cytokines, including tumor necrosis factor-a, IL-8, and macrophage inflammatory protein-1a (data not shown). These data clearly illustrate that filovirus-like particles are highly immunogenic to and induce maturation of DCs.
Induction of strong antibody responses and dose-dependent protection after vaccination with baculovirus-derived eVLPs in QS-21 adjuvant. C57BL/6 mice were vaccinated twice with equivalent quantities of baculovirus-or mammalian 293T cellderived eVLPs containing GP, VP40, and NP in the presence of the saponin derivative QS-21. Mice vaccinated with eVLPs from either mammalian or insect cells developed strong anti-EBOV antibodies in a dose-dependent manner (figure 6A and 6B), whereas mice vaccinated with QS-21 alone did not develop detectable EBOV-specific antibodies ( figure 6A and 6B) . Furthermore, mice vaccinated with the insect cell-derived eVLPs developed T cell responses to known immunogenic epitopes within GP, NP, and VP40 (table 1) , as has been demonstrated previously for mammalian 293T cell-derived eVLPs and other EBOV vaccines [15, 31, 35, 36] .
To determine the in vivo efficacy of the baculovirus-derived eVLPs, vaccinated mice were infected with mouse-adapted EBOV. Both the mammalian 293T cell-and baculovirus-derived eVLP vaccines provided high levels of protection from a lethal EBOV challenge in a dose-dependent manner, with complete protection observed at the highest doses and partial protection at doses that were 5-10-fold lower ( figure 6C and 6D) . Vaccination with QS-21 alone did not provide protection against lethal EBOV challenge.
DISCUSSION
eVLPs and mVLPs produced in mammalian cells are effective vaccines against filoviral infections in rodents and nonhuman primates (data not shown) [11, 13, 14] . In the current study, we successfully produced eVLPs and mVLPs by using a baculovirus expression system. Insect cell-derived eVLPs matured human monocyte-derived DCs. Mice vaccinated with VLPs generated by use of the baculovirus/insect cell system developed strong humoral and cellular responses, similar to those of mice vaccinated with mammalian 293T cell-derived VLPs. The mice vaccinated with insect cell-derived VLPs survived lethal EBOV challenge, suggesting that the insect cell-derived VLPs are as effective as VLPs produced in mammalian cells at similar antigen doses.
Baculovirus-derived VLPs with very similar properties to mammalian-derived eVLPs and mVLPs were easily made in large quantities [5, 8, 11, 23] . The amount of VLPs released into 1 L of culture supernatant of insect cells was at least 5-20 times more than that spontaneously released into the culture supernatants of adherent mammalian 293T cells. Furthermore, the cost of producing proteins by means of baculovirus expression systems is much lower than the cost of expensive, lipid-based transfection reagents for mammalian cell lines. In addition, we found that the baculovirus-derived VLPs were highly stable for 1-6 months, as determined by means of Western blotting, electron microscopy, and rodent efficacy studies (figure 3A and 3B; data not shown). These data provide further evidence that VLPs are a scaleable, stable, and highly desirable vaccine candidate against filoviruses.
On the basis of comparative studies with mammalian-derived eVLPs, the baculovirus-derived eVLPs were found to induce similar immune responses. Not only did both types of eVLPs induce maturation and activation of human DCs, the baculovirus-derived eVLPs induced strong antibody and T cell responses that were of the same nature and order of those induced by mammalian 293T cell-derived eVLPs ( figure 4 and table 1 ). Determining whether nonhuman primates will develop similar humoral and cellular responses to mammalian 293T cell-and insect cell-derived VLPs is extremely important. Future studies will determine which doses and vaccine schedules result in complete protection by eVLP and mVLP vaccines in nonhuman primates.
As found in the current and previous studies, glycosylation of EBOV GP molecules produced in insect cells appeared to be different from that in mammalian cells [20] [21] [22] 37] . For instance, the insect cell-derived EBOV GP migrated slightly faster than mammalian-derived GP; however, MARV GP has the same molecular size when expressed in either mammalian or insect cells ( figures 1 and 4) . Also, using Western blotting, we found that our pool of MARV-specific GP monoclonal antibodies ( ) did not seem to recognize the baculovirus-or n p 3 mammalian cell-derived MARV GP. Therefore, further studies to identify the differences in glycosylation between insect celland mammalian cell-derived VLPs may enhance our understanding of the role of glycosylation differences in the efficacy of filovirus vaccination. However, we expect that the observed differences will be very similar to those reported previously [20] [21] [22] 37] . The differences in N-linked glycosylation between insect and mammalian cells are well defined; as a result, insect cells now can be engineered to produce mammalian-like glycosylated proteins [32, 33] .
Baculovirus-derived subunit vaccines are currently being generated for a multitude of pathogens [16] [17] [18] [19] 38] , and baculovirus-derived Norwalk VLPs and papillomavirus-like particles derived from insect cells have been tested in human volunteers as recently as 10 years ago [38] . Currently, no baculovirus-derived proteins have been approved by the US Food and Drug Administration, although several appear to be on the verge of acceptance, including Provenge, a prostate cancer immunotherapy from Dendreon (http://www.dendreon.com); Ceravix, a papillomavirus vaccine from GlaxoSmithKline (http: //www.gsk.com); and FluBIOk , a non-egg-based flu vaccine from Protein Sciences (http://www.proteinsciences.com). Although the first baculovirus-derived protein therapeutic or vaccine to be approved will receive intense scrutiny, subsequent candidates will certainly move through the process more easily. Valid concerns for baculovirus-derived proteins include residual trace amounts of baculovirus or insect cells within preparations and their induction of immune responses [39, 40] . Nonetheless, many more proteins produced in insect cells con- NOTE. BALB/c mice were vaccinated with various doses of baculovirusderived eVLPs with the saponin-derived adjuvant QS-21. At 7 days after the last vaccination, 3 mice from each group were assessed ex vivo for cellular responses to previously described Zaire Ebola virus T cell epitopes in glycoprotein (GP), nucleoprotein (NP), and VP40 [15, 31, 35, 36] . Negative control samples included diluted DMSO and a Lassa virus N peptide (RPLSAGVYMGNLSSQ).
a Splenocytes were used ex vivo for identification of peptides that induced tinue to enter the clinical trials stage of testing, and the future use of baculovirus-derived proteins in humans seems highly likely. When considered together with previous data, the results of our current studies suggest that baculovirus-derived eVLPs and mVLPs represent a promising and safe vaccine candidate for protection against filoviral infections in humans. The use of a nonreplicating, subunit vaccine such as that based on VLPs may be highly advantageous for use in Africa, where the populations affected by outbreaks of filoviral infection are often dehydrated, malnourished, and immunocompromised owing to concurrent parasitic and viral infections, including infection with human immunodeficiency virus.
